"21-ICRAD" Nucleic NanoVaccines for Fish

“21-ICRAD”鱼类核酸纳米疫苗

• 批准号: BB/V019902/1
• 负责人: Samuel Martin
• 金额: $ 33.38万
• 依托单位: University of Aberdeen
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2021
• 资助国家: 英国
• 起止时间: 2021 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=BB%2FV019902%2F1
• 关键词: 21; ICRAD; Nucleic; NanoVaccines; Fish

Aquaculture is the fastest growing food production sector, but it is significantly constrained by infectious diseases. Impact of viral infectionson fish health and welfare is particularly strong, involving important economic losses, and only few vaccines are available. Therefore, it is ofparamount importance to develop new vaccines to prevent fish viral diseases for the development of a sustainable aquaculture.Experimental DNA vaccines against fish viral infections have been developed, some providing high protection but they are injected andcannot be easily administered to young fish. Importantly, several DNA vaccines have been recently made commercially available but remainexpensive. mRNA vaccines hold much hope, but they are just beginning to be tested in fish. In mammals, they often induce strongresponses and good protection. They appear to be fast to produce and safer than DNA vaccines as they should not integrate into hostgenomes.In this context, the NucNanoFish project proposes to establish a nucleic acid platform using biodegradable nanoparticles for efficientdelivery of vaccines, through intra-muscular (IM) or oral/immersion routes, against to well-known viral diseases of severalEuropean farmed fish species. We have selected four different relevant host-pathogen models through cutting edge expertise of eachconsortium's partner. NucNanoFish will design, produce and test DNA/mRNA nucleic acid vaccines loaded or not onto safe-by-designLipoNanoParticles (LNP). LNP are based on a PLA/PLGA (Poly-Lactic/Glycolic Acid) core surrounded with a lipid corona. We hypothesize thattheir efficient uptake by mucosa or the recruitment of Antigen Presenting Cells (APC) at the site of injection will favour a protective immuneICRAD NucNanoFish - ID: 10 3 of 51response at the portal of entry of each relevant virus. To achieve these goals, NucNanoFish has assembled a consortium of six partners, withhighly complementary expertise: one in nanodelivery of antigen and mRNA using LNP, four groups of fish immunovirologists / vaccinologistsand a biotech company in DNA production.

水产养殖是增长最快的粮食生产部门，但它受到传染病的严重制约。病毒感染对鱼类健康和福利的影响特别强烈，造成重大经济损失，而且可用的疫苗很少。因此，开发新的疫苗来预防鱼类病毒性疾病对于可持续水产养殖的发展至关重要。针对鱼类病毒感染的实验性DNA疫苗已经开发出来，其中一些疫苗提供了很高的保护作用，但它们是注射式的，不能轻易地对幼鱼进行注射。重要的是，几种 DNA 疫苗最近已投入商业使用，但价格仍然昂贵。 mRNA 疫苗充满希望，但它们才刚刚开始在鱼类身上进行测试。在哺乳动物中，它们通常会引起强烈的反应和良好的保护。它们似乎生产速度快，而且比 DNA 疫苗更安全，因为它们不应整合到宿主基因组中。在这种背景下，NucNanoFish 项目建议建立一个使用可生物降解纳米粒子的核酸平台，通过肌肉内 (IM) 或口服/浸泡途径，可对抗多种欧洲养殖鱼类的众所周知的病毒性疾病。我们通过每个联盟合作伙伴的尖端专业知识选择了四种不同的相关宿主病原体模型。 NucNanoFish 将设计、生产和测试加载或未加载到安全设计的 LipoNanoParticles (LNP) 上的 DNA/mRNA 核酸疫苗。 LNP 基于被脂质冠层包围的 PLA/PLGA（聚乳酸/乙醇酸）核心。我们假设它们被粘膜有效吸收或在注射部位招募抗原呈递细胞 (APC) 将有利于在每种相关病毒的入口处产生保护性免疫 ICRAD NucNanoFish - ID: 10 3 of 51 反应。为了实现这些目标，NucNanoFish 组建了一个由六个合作伙​​伴组成的联盟，这些合作伙伴拥有高度互补的专业知识：其中一个合作伙伴使用 LNP 进行抗原和 mRNA 的纳米传递，四组鱼类免疫病毒学家/疫苗学家以及一家从事 DNA 生产的生物技术公司。